Myocardial Perfusion Imaging in the Pediatric Population Peter Gardiner, MB ChB, MRCP Vice President, Medical Sciences Bristol-Myers Squibb Medical Imaging.

Slides:



Advertisements
Similar presentations
PET AND PET/CT IN ISCHEMIC HEART DISEASE
Advertisements

B. C. Kansupada, MD, HeartCare Assoc. ACC chapter talk 4/28/06.
Combination Products and Mutually Conforming Labeling David Eveleth Pfizer Inc.
Patient Health & Medical History
A-1 Pravastatin-Aspirin Introduction Todd Baumgartner, MD, MPH Vice President Regulatory Sciences Pharmaceutical Research Institute Bristol-Myers Squibb.
FDA Perspective Sally Loewke, M.D. Acting Division Director
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Title Sadeghi Ramin, MD Nuclear Medicine Research Center, Mashhad University of Medical Sciences.
Neonatal/Juvenile Animal Safety Studies Kenneth L. Hastings, Dr.P.H., D.A.B.T. Office of New Drugs, CDER.
CURRENT STATUS OF STRESS TESTING JOHN HAMATY D.O..
Prescreening ä To optimize safety ä To permit the development of a sound and effective exercise prescription.
Modalities of Cardiac Stress Test
CONTRAST AGENTS AND RADIOPHARMACEUTICALS IN CHILDREN WITH CARDIAC DISEASE: SHOULD THEIR USE BE STUDIED? John C. Ring, MD, FAAP, FACC Associate Professor.
Development of Clinical Pathways to Streamline Care for Patients Presenting with Suspected Cardiac Chest Pain Background The National Heart Foundation.
Clinical Pharmacy Basma Y. Kentab MSc..
Diagnostic Stress Testing
John N. Hamaty D.O. Second year student module
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
Management of Stable Angina SIGN 96
Cardiovascular System
CLINICAL EXERCISE TESTING To evaluate person’s ability to tolerate increasing levels of work output parameters measured include but are not limited to.
1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.
Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Radiophamaceuticals in Nuclear Cardiac Imaging Vasken Dilsizian, M.D. Professor of Medicine and Radiology Director of Cardiovascular Nuclear Medicine and.
Cardio Investigations. Patients presenting with chest pain may be identified as having definite or possible angina from their history alone. Risk Factor.
Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.
Stress testing patients on oral dipyridamole Dr Parthi Arumugam Consultant Nuclear Physician Nuclear Medicine Centre Manchester Royal Infirmary.
Lesson 3 How to diagnose Coronary Artery Disease? Diagnostic.
April 2005 How Patients Can Benefit From Molecular Imaging Paula M. Jacobs, Ph.D Vice President Advanced Magnetics, Inc.
Roles of Nuclear Cardiology, Cardiac Computed Tomography Cardiac Magnetic Resonance: Assessment of Patients with Suspected Coronary Artery Disease INT.
RISK STRATIFICATION. Established by the CACR in Sept National Guidelines Committee The committee acknowledged the support of the Canadian Cardiovascular.
C-BR- 1 Raptiva ™ (efalizumab) Benefit:Risk Assessment Charles Johnson, MB, ChB Senior Director Head of Specialty Biotherapeutics Genentech, Inc.
Fospropofol for sedation
Trial Design Issues Associated with Evaluation of Distal Protection Devices in Diseased Saphenous Vein Grafts Bram D. Zuckerman, MD, FACC Medical Officer,
How To Design a Clinical Trial
A-1 Introduction Pravastatin-Aspirin 7asdf Fred T. Fiedorek, M.D. Vice President, Clinical Design & Evaluation, Metabolics Pharmaceutical Research Institute.
Background Derma-Smoothe/FS ® (Fluocinolone acetonide ) Contains 0.01% fluocinolone acetonide in an oil base solution, Categorized as a low to medium potency.
Diagnostic reference levels in Medical Imaging. Concept and practice
Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,
Baseline Characteristics of Patients Referred for Stress Myocardial Perfusion Testing by Erectile Function Classification James K. Min, et al, Arch Intern.
Cardiovascular and Renal Drugs Advisory Committee
Adult Echocardiography Lecture 10 Coronary Anatomy
Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.
Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee July 15, 2003 Steven Hirschfeld, MD PhD CAPT USPHS Division of Oncology Drug.
Hepatitis C: Perspective on Drug Development Issues Debra Birnkrant, M.D. Director, Division of Antiviral Products FDA Antiviral Drugs Advisory Committee.
TAHAR EL KANDOUSSI, SARA ECHERKI, NAWAL DOGHMI, MOHAMED CHERTI. SEcurite de l’Echocardiographie de stress : plutôt l’effort. Cardiology B Department, Ibn.
Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.
Viagra (sildenafil citrate): Extensive Clinical and Post-Marketing Experience Michael Sweeney, MD Senior Medical Director Pfizer Inc.
Topic #1: EOP2A Meetings Please comment on the goals of the proposed EOP2A meeting and the impact that such meetings could have on optimizing dose selection.
Screening for CAD Nuclear Medicine prospective S.R.Zakavi,MD,IBNM Nuclear Medicine Research Center Mashhad University of Medical Sciences.
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology The EXERRT trial – “EXErcise to Regadenoson in Recovery.
Cardiac Indices in Myocardial Perfusion Scan and Their Impact on the Patient's Prognosis
How To Design a Clinical Trial
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Adenosine-stress myocardial perfusion imaging in octogenarians:
Multi Modality Approach to Diagnosis of Ischemia in Post CABG Cases
UAB medical Center, Birmingham VA Medical Center
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology The Prognostic value of Heart Rate Response during Vasodilator.
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Feasibility and safety of exercise stress testing using.
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Added prognostic value of left ventricular shape by.
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Prediction of 14-year cardiovascular outcomes by dobutamine.
A Recommendation from Diagnosis and Treatment of Low Back Pain: A Joint Clinical Practice Guideline from ACOP and APS By Rhys Dela Cruz, Angela Hickey,
Journal of Nuclear Cardiology | Official Journal of the American Society of Nuclear Cardiology Regadenoson Use in Chronic Kidney Disease and End-Stage.
The Role of Stress Cardiac Magnetic Resonance in Women
Considerations for Percutaneous Coronary Intervention (PCI)
Are We Closer to Personalized Medicine in MS?
Understanding PAD.
NUCLEAR CARDIOLOGY- BASICS
Clinical case report platform
Receiver operator curve plots for prognostication of 5-year and 12-year all-cause (A and C, respectively) and cardiovascular mortality (B and D, respectively)
Presentation transcript:

Myocardial Perfusion Imaging in the Pediatric Population Peter Gardiner, MB ChB, MRCP Vice President, Medical Sciences Bristol-Myers Squibb Medical Imaging

A worldwide leader in cardiovascular imaging research Product line includes: –Cardiolite ® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) –Definity ® (Vial for Perflutren Lipid Microsphere Injectable Suspension) Committed to appropriate evaluation of imaging drugs and cardiac imaging procedures in children Focus on nuclear myocardial perfusion imaging (MPI)

Nuclear Myocardial Perfusion Imaging Only modality approved by FDA for assessment of myocardial perfusion and function >13 years experience with Tc99m agents Indications: Perfusion; function; exercise and pharmacologic stress Extensive literature documenting use in diagnosis, prognosis and risk stratification Safe and well tolerated Continued growth in usage

Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection) Launched in US in 1991 Indications: myocardial perfusion and function; exercise and pharmacologic stress; developing information for use in patient management decisions Leadership position: –Clinical use –Continued significant investment in Clinical Research and Education

Nuclear Myocardial Perfusion Imaging in Children Lack of substantial, well-controlled clinical studies to define dosing and efficacy Usage - ~ 2-3,000 studies in 2002 Patient populations: –Kawasaki’s Disease –Cardiac transplant vasculopathy –Cardiomyopathies (including hypertrophic and drug- induced) –Congenital heart disease, including anomalous LCA

Nuclear Myocardial Perfusion Imaging in Children Advantages –Extensive experience and FDA approved for use in adults –Operator independent –Reduced dose and duration of imaging with Tc99m based agents Disadvantages –Radiation exposure –Limited information on dosing (only weight-based) –Lack of substantial efficacy data

Nuclear Myocardial Perfusion Imaging in Children Summary Nuclear imaging is the only modality approved by FDA for assessment of myocardial perfusion and function in adults Extensive experience in adults Limited and variable experience in children Bristol-Myers Squibb Medical Imaging (BMS MI) supports FDA’s initiatives to evaluate nuclear cardiac imaging in children